Published online Sep 28, 2015. doi: 10.3748/wjg.v21.i36.10358
Peer-review started: February 26, 2015
First decision: March 26, 2015
Revised: April 28, 2015
Accepted: July 15, 2015
Article in press: July 15, 2015
Published online: September 28, 2015
AIM: To investigate the association between tumor protein 53 (TP53) codon 72 polymorphisms and the risk for inflammatory bowel disease (IBD) development.
METHODS: Numerous genetic and epigenetic drivers have been identified for IBD including the TP53 gene. Pathogenic mutations in TP53 gene have only been reported in 50% of colorectal cancer (CRC) patients. A single nucleotide polymorphism (SNP) in the TP53 gene resulting in the presence of either arginine (Arg) or proline (Pro) or both at codon 72 was shown to alter TP53 tumor-suppressor properties. This SNP has been investigated as a risk factor for numerous cancers, including CRC. In this study we analyzed TP53 codon 72 polymorphism distribution in 461 IBD, 181 primary sclerosing cholangitis patients and 62 healthy controls. Genotyping of TP53 was performed by sequencing and restriction fragment length polymorphism analysis of genomic DNA extracted from peripheral blood.
RESULTS: The most frequent TP53 genotype in IBD patients was Arg/Arg occurring in 54%-64% of cases (and in only 32% of controls). Arg/Pro was the most prevalent genotype in controls (53%) and less common in patients (31%-40%). Pro/Pro frequency was not significantly different between controls and IBD patients.
CONCLUSION: The data suggests that the TP53 codon 72 Arg/Arg genotype is associated with increased risk for IBD development.
Core tip: Tumor protein 53 (TP53) codon 72 polymorphism distribution was analyzed by RFLP in 461 inflammatory bowel disease (IBD), 181 primary sclerosing cholangitis patents and in 62 healthy controls. The data suggests that the TP53 codon 72 Arg/Arg genotype is associated with increased risk for IBD development.